Treprostinil Palmitil

DRUG5 trials

Sponsors

Insmed Incorporated

Conditions

Pulmonary Arterial HypertensionPulmonary HypertensionPulmonary Hypertension, Interstitial Lung Disease

Phase 2

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

TerminatedNCT04791514

Insmed IncorporatedPulmonary Arterial Hypertension

Start: 2022-03-29End: 2022-08-26Updated: 2023-09-22

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

CompletedNCT05147805

Insmed IncorporatedPulmonary Arterial Hypertension

Start: 2022-08-24End: 2025-03-27Updated: 2026-03-30

A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

CompletedNCT05176951

Insmed IncorporatedPulmonary Hypertension

Start: 2022-12-22End: 2024-03-14Updated: 2025-03-17

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Active, not recruitingNCT05649748

Insmed IncorporatedPulmonary Arterial Hypertension

Start: 2023-03-07End: 2026-12-31Updated: 2026-08-20

Unknown Phase

An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Insmed IncorporatedPulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease

Updated: 2026-06-10